Surgical implications of therapeutic angiogenesis

Surgery

Volumn 125, Issue 3, 1999, Pages 243-249

  Zimmerman, Michael A ^a   Selzman, Craig H ^a,b   Harken, Alden H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOSTATIN; BETA INTERFERON; CD11B ANTIGEN; CD18 ANTIGEN; ELASTASE; ENDOSTATIN; FIBRIN; FIBRINOGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GLYCOPROTEIN; INTEGRIN; LAMININ; METALLOPROTEINASE; NEUTRALIZING ANTIBODY; PENTOSAN POLYSULFATE; PEPTIDE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROTEIN; PROTEINASE; SUCRALFATE; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CLINICAL TRIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; WOUND HEALING;

EID: 0032923313     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70233-3     Document Type: Article

References (58)

1. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs. Ann Surg 1966;164:491-502.
2. Gimbrione MA, Aster RH, Cotran RS, Corkery J, Jandl JH, Folkman J. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 1966;222:33-6.
3. Folkman J, Merzler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-88.
4. Schwartz S, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 1993;21[suppl]:S31-S49.
5. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994;267(pt 2):H 1948-54.
6. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990;9:467-74.
7. Werb Z, Banda MJ, Jones PA. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins and collagen by proteinases isolated from macrophages. J Exp Med 1980;152:1340-57.
8. Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984;259:6241-7.
9. Chapman HAJ, Stone OL. Co-operation between plasmin and elastase is elastin degradation by intact murine macrophages. Biochem J 1984;222:721-8.
10. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662-75.
11. Brooks PC, Clark RAF, Cheresh DA. Requirement of integrin αvβ3 for angiogenesis. Science 1994;264:569-71.
12. Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
13. Leavesley D, Schwartz M, Rosenfeld D, Cheresh D. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1993;121:163-70.
14. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991;20(suppl 1):103-12.
15. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991;51:6180-4.
16. Kim K, Li B, Winer J, Armanini M, Gillett N, Phillips H, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
17. Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V, Dvoark H. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
18. Leung D, Cachianes G, Kwang W-J, Goeddel D, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
19. Connolly D, Heuvelman D, Nelson R, Olander J, Eppley B, Delfino J, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
20. Mandriota S, Seghezzi G, Vassalli J-D, Ferrara N, Wasi S, Mazzieri R, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709-16.
21. Friedlander M, Brooks P, Shaffer R, Kincaid C, Varner J, Cheresh D. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270:1500-2.
22. Weich H, Iberg N, Klagsbrun M, Folkman J. Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. Growth Factors 1990;2:313-20.
23. Orr-Urteger A, Bedford M, Burakova T, Arman E, Zimmer Y, Yayon A, et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2. Dev Biol 1993;158:475-86.
24. Lorenzet R, Sobel J, Bini A, Witte L. Low molecular weight fibrinogen degradation products stimulate the release of growth factors from endothelial cells. Thromb Haemost 1992;68:357-63.
25. Pepper M, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor type 1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-8.
26. Brew E, Mitchell MB, Harken AH. Fibroblast growth factors in operative wound healing. J Am Coll Surg 1995;180:499-504.
27. Nissen N, Polverini P, Gamelli R, DiPietro L. Basic fibroblastic growth factor mediates angiogenic activity in early surgical wounds. Surgery 1996;119:457-65.
28. Davidson J, Broadley K. Manipulation of the wound-healing process with basic fibroblastic growth factor. Ann N Y Acad Sci 1991;638:306-15.
29. Greenhalgh D, Sprugel K, Murray M, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990;136:1235-46.
30. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neurotrophic ulcers of the foot. Diabetes Care 1995;18:64-9.
31. Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991;214:414-27.
32. Folkman J, Szabo S, Shing Y. Sucralfate affinity for fibroblast growth factor [abstract]. J Cell Biol 1990;111:223.
33. Koester W. Endarteritis and arteritis. Berl Klim Wochenschr 1876;13:454-5.
34. Takeshita S, Zheng L, Brogi E, Kearney M, Pu L, Ferrara N, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93:662-70.
35. Asahara T, Bauters C, Zheng L, Takeshita S, Bunting S, Ferrara N, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92:11365-71.
36. Bauters C, Asahara T, Zheng L, Takeshita S, Bunting S, Ferrera N, et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vase Surg 1995;21:314-24.
37. Isner J, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4.
38. Isner J, Peiczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al. Arterial gene transfer of naked DNA in patients with critical limb ishcemia [abstract]. Circulation 1996;94:1-591.
39. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Utsuyama M, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-3.
40. Lazarous D, Scheinowitz M, Shou M, Hodge E, Sharmini Rajanayagam M, Hunsberger S, et al. Effects of chronic systemic administration of basic fibroblastic growth factor on collateral development in the canine heart. Circulation 1995;91:145-53.
41. Schumacher B, Pecher P, von Specht B, Stegman T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 1998;97:645-50.
42. Weidner N, Semple J, Welch W, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
43. Weidner N, Carroll P, Flax J, Bulmenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
44. Nguyen M, Watanabe H, Budson A, Richie J, Hayes D, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
45. Yoshiji H, Gomez D, Shibuya M, Thorgeirsson U. Expression of vascular endothelial growth factor, and its receptors, and other angiogenic factors in breast cancer. Cancer Res 1996;56:2013-6.
46. Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Senger D, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35.
47. Phillips H, Armanini M, Stavrou D, Ferrara N, Westphal M. Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol 1993;2:913-9.
48. Tsai J-C, Goldman C, Gillespie G. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995;82:864-73.
49. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, et al. Angiogenesis as a target for tumor treatment. Oncology 1997;54:177-84.
50. Stan A, Nemati M, Pietsch T, Walter G, Dietz H. In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 1995;82:1044-52.
51. Singh R, Gutman M, Bucana C, Sanchez R, Llansa N, Fidler I. Interferon α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
52. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85:1585-92.
53. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993;53:2566-70.
54. Zukiwiski A, Gutterman J, Bui C, Sella A, Ellerhorst J, Tu S, et al. Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen independent prostate cancer (AIPCa) [abstract]. Proc Am Soc Clin Oncol 1994;13:252.
55. Levy T, Kudelka D, Steger M, Mante R, Gutterman J, Piamsomboon S, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix [abstract]. Proc Am Assoc Cancer Res 1996;37:166.
56. O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994;79:315-28.
57. Holmgren L, O'Reilly M, Folkman J. Dormancy of micrometastasis: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995;1:149-53.
58. O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.